Allarity Therapeutics Presents New Phase 2 Clinical Data for Stenoparib/2X-121 Showing Landmark Median Overall Survival Has Now Surpassed 25 Months

Core Insights - The median Overall Survival (mOS) for patients with platinum-resistant and refractory ovarian cancer receiving stenoparib exceeds 25 months, marking a significant improvement over existing therapies [1][3][4] - The clinical trial data presented at the AACR conference indicates that stenoparib shows clinical benefit in both BRCA wild-type and BRCA mutant patients, highlighting its unique mechanism of action as a dual inhibitor [2][3][5] - Stenoparib demonstrates a favorable safety profile with less myelotoxicity compared to earlier-generation PARP inhibitors, addressing the need for effective treatments in heavily pre-treated ovarian cancer patients [4][5] Clinical Trial Data - The ongoing Phase 2 trial includes patients with advanced ovarian cancer who are platinum-resistant or refractory, with a Stenoparib-specific Drug Response Predictor (DRP) score above 50 [2][3] - Two patients have been on therapy for over 24 months, including one with a wild-type BRCA gene, which typically does not respond well to PARP inhibitors [2][3] - The current Kaplan-Meier estimate for mOS has not yet been reached, with a median follow-up time of nearly 22 months, indicating promising long-term outcomes [3][4] Drug Mechanism and Development - Stenoparib is a dual-targeted inhibitor of PARP1/2 and tankyrase 1/2, with potential applications across various cancer types due to its action on the WNT signaling pathway [6][8] - Allarity Therapeutics has secured exclusive global rights for the development and commercialization of stenoparib, which was originally developed by Eisai Co. Ltd. [6][8] - The company is actively enrolling patients in a new Phase 2 trial protocol specifically for platinum-resistant or platinum-ineligible patients to expedite the drug's development towards FDA approval [3][6] Drug Response Predictor (DRP) - The DRP is utilized to select patients likely to benefit from stenoparib based on their cancer's gene expression signature, enhancing the therapeutic benefit rate [7] - The DRP platform has shown significant predictive ability for clinical outcomes across various cancer studies, supporting personalized treatment approaches [7]